« Back
Home /
PF-562271 (besylate)

PF-562271 (besylate)

Item no.	HY-10458-10mM
Manufacturer	MedChem Express
CASRN	939791-38-5
Amount	10 mM/1 mL
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 25 mg 50 mg 5 mg
Category	Oncology Neuroscience Neural Signaling Inhibitors & Compound Libraries Small Molecules By Organ Bladder Cancer
Type	Inhibitors
Specific against	other
Purity	99.17
Citations	[1]Roberts WG, et al. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res, 2008, 68(6), 1935-1944.\|[2]Lim ST, et al. FERM control of FAK function: implications for cancer therapy. Cell Cycle, 2008, 7(15), 2306-2314.\|[3]Canel M, et al. Quantitative in vivo imaging of the effects of inhibiting integrin signaling via Src and FAK on cancer cell movement: effects on E-cadherin dynamics. Cancer Res, 2010, 70(22), 9413-9422. Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.\|Anticancer Drugs. 2023 Jul 14.\|Breast Cancer Res. 2024 Mar 19;26(1):48.\|Cancer Res. 2013 May 1;73(9):2873-83.\|Carbohydr Polym. 2024 Feb 15, 326, 121637.\|Cell Death Dis. 2022 Sep 10;13(9):783.\|Cell Death Dis. 2023 Feb 24;14(2):157.\|Cell Discov. 2022 Sep 6;8(1):84.\|Cell Rep. 2023 Oct 5;42(10):113213.\|Clin Cancer Res. 2019 Jul 15;25(14):4552-4566.\|Environ Toxicol Pharmacol. 2023 Oct 20:104301.\|Eur J Cell Biol. 2024 May 28;103(2):151427.\|Harvard Medical School LINCS LIBRARY\|Int J Cancer. 2015 Oct 1;137(7):1549-59.\|J Nat Med. 2020 Sep;74(4):732-740.\|Life Sci. 2021 Jan 25;119112.\|Practical Oncology Journal. 2015, 29(5): 444-449.\|Research Square Preprint. 2021 Dec.\|Research Square Preprint. 2023 May 23.\|Sci Rep. 2018 May 8;8(1):7228.
Smiles	CS(=O)(N(C)C1=NC=CC=C1CNC2=NC(NC3=CC4=C(NC(C4)=O)C=C3)=NC=C2C(F)(F)F)=O.O=S(C5=CC=CC=C5)(O)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	VS-6062 (besylate)
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	FAK; Pyk2
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	665.66
Product Description	PF-562271 (VS-6062) besylate is a potent ATP-competitive, reversible inhibitor of FAK and Pyk2 kinase, with an IC50 of 1.5 nM and 13 nM, respectively[1].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 21.4 mg/mL (ultrasonic; warming)\|H2O: < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Protein Tyrosine Kinase/RTK
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-10458-10mM-safety-datasheet.pdf